Dementia Consortium Signs New Pharma Partner Astex Pharmaceuticals
News Oct 13, 2015
The Dementia Consortium has announced Astex Pharmaceuticals (Astex) as a new member.
The Consortium is a £3.5m cross-sector drug discovery collaboration between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai, Lilly and now Astex. Astex will bring not only knowledge and resource but additional capital investment to help fund projects.
By uniting expertise, this focused investment will bridge the gap between academic research and the pharmaceutical industry, in the search for drugs that slow the development of neurodegenerative diseases that cause dementia.
The Dementia Consortium is open to global research teams and funds robust target validation and early phase drug discovery to accelerate progress through the translational research pipeline.
To date the Consortium has awarded around £800,000 of funding for research projects focusing on Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS, also known as motor neurone disease or Lou Gehrig’s Disease), and Frontotemporal Lobar Degeneration (FTLD), the most common cause of dementia in people under the age of 50.
Dr Lee Dawson, Vice President of CNS at Astex, commented: “The biological mechanisms that underpin the pathology of dementia are incredibly complex, and new opportunities for possible therapeutic intervention can only be developed by pooling research knowledge and know-how from across academic, charity and industry sectors. Astex is excited about becoming a partner in the Dementia Consortium and we look forward to applying our expertise in drug discovery and fragment-based drug design to this endeavour.”
Dr Simon Ridley, Director of Research at Alzheimer’s Research UK, added: “We are delighted to welcome Astex on board, to broaden ties with industrial partners and bring new perspectives to the Consortium. The collaborative model of the Dementia Consortium brings world leading expertise and capabilities together, to accelerate progress from academic laboratories across the world into much sought-after treatments in the clinic.”
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Researchers Test Drug Transfer Using Placenta-On-A-ChipNews
Researchers have demonstrated the feasibility of their "organ-on-a-chip" platform in studying how drugs are transported across the human placental barrier.READ MORE
'Click Chemistry' Reactions Could Boost Cancer-Fighting Drug PotencyNews
Researchers at The Scripps Research Institute (TSRI) have developed a quick and easy way to simultaneously modify dozens of drugs or molecules to improve their disease-fighting properties.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018